SPRINGWORKS THERAPEUTICS INC (SWTX)
US85205L1070 - Common Stock
We assign a fundamental rating of 4 out of 10 to SWTX. SWTX was compared to 587 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SWTX as it has an excellent financial health rating, but there are worries on the profitability. SWTX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SWTX had negative earnings in the past year.
SWTX had a negative operating cash flow in the past year.
In the past 5 years SWTX always reported negative net income.
In the past 5 years SWTX always reported negative operating cash flow.
1.2 Ratios
SWTX has a Return On Assets (-44.79%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -51.92%, SWTX is doing good in the industry, outperforming 66.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.79% | ||
| ROE | -51.92% | ||
| ROIC | N/A |
ROA(3y)-42.42%
ROA(5y)-30.05%
ROE(3y)-47.6%
ROE(5y)-33.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 92.25%, SWTX belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
SWTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SWTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SWTX has been increased compared to 1 year ago.
SWTX has more shares outstanding than it did 5 years ago.
SWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SWTX has an Altman-Z score of 17.55. This indicates that SWTX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 17.55, SWTX belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
There is no outstanding debt for SWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 17.55 |
ROIC/WACCN/A
WACC9.14%
2.3 Liquidity
A Current Ratio of 6.41 indicates that SWTX has no problem at all paying its short term obligations.
SWTX's Current ratio of 6.41 is fine compared to the rest of the industry. SWTX outperforms 65.13% of its industry peers.
A Quick Ratio of 6.37 indicates that SWTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.37, SWTX is in the better half of the industry, outperforming 65.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.41 | ||
| Quick Ratio | 6.37 |
3. Growth
3.1 Past
SWTX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.11%.
Measured over the past years, SWTX shows a very negative growth in Revenue. The Revenue has been decreasing by -46.21% on average per year.
EPS 1Y (TTM)1.11%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-23.93%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-46.21%
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
SWTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.00% yearly.
Based on estimates for the next years, SWTX will show a very strong growth in Revenue. The Revenue will grow by 336.16% on average per year.
EPS Next Y6.66%
EPS Next 2Y14.35%
EPS Next 3Y20.11%
EPS Next 5Y12%
Revenue Next Year8080.35%
Revenue Next 2Y1449.4%
Revenue Next 3Y658.12%
Revenue Next 5Y336.16%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SWTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SWTX's earnings are expected to grow with 20.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y20.11%
5. Dividend
5.1 Amount
SWTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SPRINGWORKS THERAPEUTICS INC
NASDAQ:SWTX (5/6/2024, 7:00:00 PM)
After market: 46.32 0 (0%)46.32
+1.21 (+2.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.43B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.79% | ||
| ROE | -51.92% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.25% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.41 | ||
| Quick Ratio | 6.37 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)1.11%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y6.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3Y-46.21%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y